However, as the use of TKIs in ABL1r T-ALL patients has not been as extensively trialed and the benefit is not as clear, TKIs are not currently included in standard therapeutic regimens in T-ALL even when an ABL-class rearrangement is present. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.